Check out our review of high-impact #geriheme & #gerionc abstracts from ASH #ASH23 , now published Journal of Geriatric Oncology. Patient-reported outcomes abstracts are also featured!
sciencedirect.com/science/articl…

Want a comprehensive overview of the FDA-approved CD19 #CART products & CD20 bispecifics available for #DLBCL and an insight into their optimal sequencing?

Watch our wonderful interview with manalikamdar (@CUCancerCenter):

👉 ow.ly/YNcy50R7mwE

#LYMsm #Lymphoma #HemOnc

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

A huge congratulations to Drs. Michael Sargent Binkley & Jamie Flerlage and the entire GLOW: Global nLPHL One Working Group team on publication of an NLPHL-specific prognostic score (LP-IPS) in Journal of Clinical Oncology. Deeply grateful to have participated in this high-impact study! #lymsm #NLPHLsm ascopubs.org/doi/pdf/10.120…

Spotted! Our own Fernando Holguin, MD, sporting his new, sparkling white Clinical Excellence Society lab coat while on service this week. Have our other Clinical Excellence Society members broken in their white coats yet?

Today at CU Anschutz Division of Hematology Denver ASH Review: Brad Haverkos presenting better PFS and less deaths with N-AVD in older adults on S1826, and PD1 CPI before ASCT in r/r cHL➡️better PFS. #lymsm

Last night we celebrated 21 incredible faculty members at DOM's first-ever Clinical Excellence Society induction ceremony. Chair Vineet Chopra said these clinicians are “the best of the best…the doctors patients get on a plane to see.” Read more: bit.ly/49e7M0D

Dan P. in DC!! 🇺🇸

Honored to help the Lymphoma Research Foundation disseminate the latest updates in the field along side John P. Leonard, MD and @JamnieFlerlage

If you missed it, you can stream it too!

CD5 represents an easy and exportable biomarker, appears to be a surrogate for molecular subtypes in DLBCL, and should be characterized in ongoing and future studies of targeted agents that perturb BCR signaling. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

New over on the CU Anschutz Division of Hematology newsroom:
- The ASCO Post Daily News article by Drs. Cassandra Duarte & Ajay Major, MD, MBA (dailynews.ascopubs.org/do/understandi…)
- #ASH23 Blood Journal Education Session article about CAR-T vs BiTEs in #lymsm by Drs. Ajay Major, MD, MBA & manalikamdar (ashpublications.org/hematology/art…)

It was an honor to celebrate our fearless leader Jordan Lab on his 10 years as chief of the division. CU Anschutz Division of Hematology CU Department of Medicine

A standing ovation-of course!

Congratulations to Dr. Cassandra Duarte CU Anschutz Hematology/Oncology Fellowship on her publication ASCO Daily News about CAR-T versus ASCT in R/R DLBCL! #lymsm #celltherapy cc CU Anschutz Division of Hematology CU School of Medicine CU Lymphoma Program
dailynews.ascopubs.org/do/understandi…

Big milestone for the Colorado Center for Personalized Medicine: Genetic results have been returned to over 30K patients! This partnership between CU Anschutz Medical Campus and uchealth is bringing precision medicine to the point of care at an unprecedented scale.
news.cuanschutz.edu/news-stories/t…

Very important paper just out. Congrats to all the authors. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy | Blood | American Society of Hematology ashpublications.org/blood/article/…

A great team effort: LBCL is getting complicated!
R/R guideline to follow....
doi.org/10.1111/bjh.19…

Andrew Davies Sridhar Chaganti Pam McKay Toby Eyre Sally Barrington Andrea Kuhnl Kate Cwynarski #GMcIlroy #CBurton #TIllidge @NKalakonda LymphomaAction BSH - Haematology

Nametag or Zoom link...either preference, you are invited to join us for the 2024 Denver ASH Review!

Saturday, February 10th - a free CE event with complimentary parking, breakfast and lunch :)

bit.ly/DenverASHRevie…

Our CU Lymphoma Program T/NK-cell expert Dr. Brad Haverkos was just published Haematologica as senior author of a phase I/II trial of tenalisib + romidepsin in R/R T-cell lymphomas. #lymsm cc Bloodbytes pubmed.ncbi.nlm.nih.gov/37439343/

NEW from Rahul Banerjee, MD, FACP David Maloney & colleagues: Answering the 'Doctor, can CAR-T therapy cause cancer?' question in clinic Blood Advances Immortal time bias = if pts don't live longer (thanks to CAR T), secondary malignancy won't be observed
#cancer #immunotherapy …

The ASH #ASH23 Education Book is finally here! Check out our approach and algorithm to bispecific antibodies versus CAR-T for relapsed/refractory DLBCL. cc manalikamdar #lymsm #celltherapy ashpublications.org/hematology/art…